The FDA has granted breakthrough therapy designation to BCB-276 for the treatment of diffuse intrinsic pontine glioma (DIPG), an incurable pediatric brain tumor. BCB-276 is an investigational chimeric ...

The definite diagnosis of CAA relies on histopathological analysis from brain autopsy or biopsy samples. Nonetheless, probable diagnosis could be inferred according to the Boston criteria, based on ...

Her work provides new insights into how long-term patterns of obesity relate to changes in brain anatomy and cognitive performance, offering a more accurate understanding of obesity’s lasting impact ...